BRPI0514891A - composição contendo derivados de prostaglandina e uso da referida composição - Google Patents

composição contendo derivados de prostaglandina e uso da referida composição

Info

Publication number
BRPI0514891A
BRPI0514891A BRPI0514891-0A BRPI0514891A BRPI0514891A BR PI0514891 A BRPI0514891 A BR PI0514891A BR PI0514891 A BRPI0514891 A BR PI0514891A BR PI0514891 A BRPI0514891 A BR PI0514891A
Authority
BR
Brazil
Prior art keywords
composition
human subject
effective
composition containing
subject
Prior art date
Application number
BRPI0514891-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Ryuji Ueno
Original Assignee
Sucampo Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35229739&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0514891(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sucampo Ag filed Critical Sucampo Ag
Publication of BRPI0514891A publication Critical patent/BRPI0514891A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/94—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0514891-0A 2004-09-02 2005-09-01 composição contendo derivados de prostaglandina e uso da referida composição BRPI0514891A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US60652104P 2004-09-02 2004-09-02
US66631705P 2005-03-30 2005-03-30
US66659305P 2005-03-31 2005-03-31
PCT/JP2005/016464 WO2006025599A1 (en) 2004-09-02 2005-09-01 Prostaglandin derivatives for treating gastrointestinal disorder

Publications (1)

Publication Number Publication Date
BRPI0514891A true BRPI0514891A (pt) 2008-06-24

Family

ID=35229739

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0514891-0A BRPI0514891A (pt) 2004-09-02 2005-09-01 composição contendo derivados de prostaglandina e uso da referida composição

Country Status (16)

Country Link
US (2) US8748481B2 (https=)
EP (1) EP1791545B1 (https=)
JP (4) JP2008511541A (https=)
KR (4) KR20180033310A (https=)
CN (1) CN102885821A (https=)
AR (1) AR050626A1 (https=)
AU (1) AU2005278323B2 (https=)
BR (1) BRPI0514891A (https=)
CA (1) CA2577284A1 (https=)
ES (1) ES2603381T3 (https=)
IL (1) IL181332A (https=)
MX (1) MX2007002602A (https=)
NO (1) NO340989B1 (https=)
NZ (1) NZ553434A (https=)
TW (1) TWI387454B (https=)
WO (1) WO2006025599A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1562604T3 (da) * 2002-10-23 2012-04-02 Sucampo Ag Prostaglandinforbindelser til behandling af fedme
ATE489096T1 (de) * 2003-07-03 2010-12-15 Sucampo Ag Pharmazeutische magensaftresistent überzogene zusammensetzung enthaltend prostaglandin-analoga als chloridkanalöffner
EP1984027B1 (en) * 2006-01-24 2015-12-30 R-Tech Ueno, Ltd. Pharmaceutical composition comprising a bi-cyclic compound and method for stabilizing the bi-cyclic compound
US20090030072A1 (en) * 2007-07-03 2009-01-29 Sucampo Ag Pharmaceutical combination of opioid and prostaglandin compound
JP2015514681A (ja) * 2012-04-23 2015-05-21 スキャンポ・アーゲーＳｕｃａｍｐｏ ＡＧ 下痢を伴う過敏性腸症候群の処置方法
MY176162A (en) * 2013-02-04 2020-07-24 Taisho Pharmaceutical Co Ltd Prophylactic or therapeutic drug for constipation
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5428062A (en) 1987-01-28 1995-06-27 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti ulcers containing same
US5225439A (en) 1987-01-28 1993-07-06 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti ulcers containing same
US5166174A (en) 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
US5317032A (en) * 1987-10-02 1994-05-31 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Prostaglandin cathartic
RU2695274C3 (ru) 1999-10-15 2020-11-09 Сукампо Аг Новые композиции и способы их стабилизации
US6414016B1 (en) 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition
TWI302100B (en) * 2001-05-02 2008-10-21 Sucampo Ag Composition for treating drug-induced constipation
WO2002094274A1 (en) 2001-05-18 2002-11-28 Sucampo Ag Cathartic composition
EP1420794B1 (en) * 2001-08-31 2017-12-27 Sucampo AG Prostaglandin analogs as chloride channel openers
AR037524A1 (es) * 2001-11-14 2004-11-17 Sucampo Ag Unidad de dosificacion que comprende un analogo de prostaglandina para el tratamiento de la constipacion
TWI263505B (en) 2001-11-19 2006-10-11 Sucampo Ag Pharmaceutical composition comprising a C1C-2 channel opener
BRPI0317740B8 (pt) * 2002-12-27 2021-05-25 Sucampo Ag uso do composto 13,14-diidro-15-ceto-16,16-diflúorprostaglandina e1
ATE489096T1 (de) 2003-07-03 2010-12-15 Sucampo Ag Pharmazeutische magensaftresistent überzogene zusammensetzung enthaltend prostaglandin-analoga als chloridkanalöffner

Also Published As

Publication number Publication date
JP6408426B2 (ja) 2018-10-17
TWI387454B (zh) 2013-03-01
AR050626A1 (es) 2006-11-08
ES2603381T3 (es) 2017-02-27
EP1791545A1 (en) 2007-06-06
KR20170003712A (ko) 2017-01-09
KR20070048221A (ko) 2007-05-08
US20060063830A1 (en) 2006-03-23
EP1791545B1 (en) 2016-08-31
NO20071704L (no) 2007-05-31
US8748481B2 (en) 2014-06-10
NZ553434A (en) 2010-01-29
JP2018150354A (ja) 2018-09-27
WO2006025599A1 (en) 2006-03-09
KR20140019006A (ko) 2014-02-13
AU2005278323B2 (en) 2011-03-17
JP2015166377A (ja) 2015-09-24
JP2013049688A (ja) 2013-03-14
JP2008511541A (ja) 2008-04-17
US20140315994A1 (en) 2014-10-23
KR20180033310A (ko) 2018-04-02
IL181332A (en) 2015-09-24
MX2007002602A (es) 2007-04-25
CN102885821A (zh) 2013-01-23
TW200612901A (en) 2006-05-01
CA2577284A1 (en) 2006-03-09
AU2005278323A1 (en) 2006-03-09
NO340989B1 (no) 2017-07-31
IL181332A0 (en) 2007-07-04

Similar Documents

Publication Publication Date Title
AP1041A (en) Prevention of loss and restoration of bone mass by certain prostaglandin agonists.
JP5827326B2 (ja) リン酸輸送を阻害する化合物及び方法
NO20071042L (no) 5-substituerte 2-fenylaminobenzamider som MEK-inhibitorer
BR0308816A (pt) Tiazolidina-4-carbonitrilas e análogos e seus usos como inibidores da dipeptil-peptidas
BR0314943A (pt) Inibidores da proteìna reguladora da condutância transmembrana da fibrose cìstica e usos destes
BR112022004587A2 (pt) Métodos para tratar narcolepsia tipo 1, diminuir eventos tipo cataplexia, aumentar concentração de cálcio intracelular, aumentar latência de sono em manutenção de teste de insônia, melhorar classificação de escaça de sonolência de karolinska, tratar uma doença associada a nível de orexina reduzido, aumentar alerta, melhorar classificação de escala de sonolência epworth, e, composição farmacêutica
ES2530047T3 (es) Material y métodos para el tratamiento de trastornos del desarrollo que incluyen autismo idiopático y comórbido
CN107835695B (zh) 用于治疗自闭症的组合物和方法
BRPI0514891A (pt) composição contendo derivados de prostaglandina e uso da referida composição
Caserio Treatment of alopecia areata with squaric acid dibutylester
Ritz et al. Sulfate‐reducing bacteria slow intestinal transit in a bismuth‐reversible fashion in mice
BR9914266A (pt) Derivados de propanolamina substituìdos por heterociclos, processos para a sua preparação, medicamentos contendo estes compostos e seu emprego
Soto et al. c-Fos activity in the insular cortex, nucleus accumbens and basolateral amygdala following the intraperitoneal injection of saccharin and lithium chloride
BR0208939A (pt) Método e agente para tratamento oftálmikco tópico de doenças inflamatórias oculares
BR0215904A (pt) Métodos e composições para prover glutamina
BR0311363A (pt) Formulação farmacêutica de liberação imediata, uso da mesma, e, método para tratar um distúrbio cardiovascular em um paciente
CY1112638T1 (el) Χρηση των παραγωγων ινδολιου ως ενεργοποιητες νurr-1 για την θεραπεια νοσου ραrκινsον
La Fuente et al. Erectile dysfunction is associated with defective L-cysteine/hydrogen sulfide pathway in human corpus cavernosum and penile arteries
ES2744206T3 (es) Combinaciones farmacéuticas que comprenden testosterona y tadalafilo en el tratamiento de la disfunción sexual femenina
NO20064982L (no) 1,3,4-oksadiazol-2-oner som PPAR delta modulatorer og anvendelse derav
US20190142825A1 (en) Role of N-2-Hydroxy-Ethyl-Piperazine-N'-2-Ethane Sulfonic Acid (HEPES) in Pain Control and Reversal of Demyelinization Injury
BR0308415A (pt) Métodos de tratamento de diabetes usando-se inibidores de pde11a
BR112023001726A2 (pt) Agente terapêutico para danos nos nervos
Wadhwa The history of drug development in psychiatry: a lesson in serendipity
NO971899L (no) Anvendelse av £R-(Z)|-<alfa>-(metoksyimino)-<alfa>-(1 azabicyklo £2.2.2| okt-3-yl) acetonitril til å redusere amyloid <beta>-A4-dannelse hos Alzheimer's sykdom

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]